Institute of Biotechnology, Academy of Military Medical Sciences, China

Chengdu Olymvax Biopharmaceuticals Inc.

Erling Feng

Li Zhu

Peng Sun

Jun Wu

Hengliang Wang

Chao Pan

Bin Wang

Bo Liu

Xin Gong

Ming Zeng

Shaohong Chang

Xin Li

Zhicheng Liu

Tiantian Wang

Zhehui Peng

Dongshu Wang

Xiankai Liu

The present invention discloses aimmunogenic protein and its composition and application. This invention provides a protein, comprising 39 amino acids of the N-terminal α-helix part of the Ata protein transport functional domain ofand an adjuvant protein; amino acid sequence of said 39 amino acids of the N-terminal α-helix part of the Ata protein transport functional domain ofis shown as the 127-165amino acid residues of SEQ ID NO:2. In present invention the 39 amino acids of the N-terminal α-helix part of surface protein Ata (trimeric autotransporter) of, was took to fuse with CTB, and express in BL21. The protein was purified by a nickel column, and used to intraperitoneally immunize mouses by 2.5 μg/mouse. Its immunogenicity and immunoprotection was verified through the animal experiments, which proves it has a good effect of anti-infection of

immunogenic protein and composition and application thereof

The invention provided a method for preparing a bacterial polysaccharide-modified recombinant fusion protein and use of the bacterial polysaccharide-modified recombinant fusion protein. The method comprises: co-expressing a recombinant fusion protein and theO-oligosaccharyltransferase PglL in an O-antigen ligase gene-defective bacterium, and linking a polysaccharides endogenous or exogenous for the bacterium to the recombinant fusion protein by the O-oligosaccharyltransferase PglL, to obtain the bacterial polysaccharide-modified recombinant fusion protein. The protein can be used for preparing antibodies against bacterial polysaccharides and vaccines.

Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use of the protein

The present invention discloses aA with an O-antigen having an extended carbohydrate chain and uses thereof. The method comprises the following steps: inactivating an cld gene encoding an enzyme controlling chain length of O-antigen of aA strain to obtain aA with deletion of cld gene; allowing overexpression of cldgene encoding an enzyme controlling chain length of O-antigen ofinA deficient in the cld gene encoding an enzyme controlling chain length of O-antigen, so as to extend carbohydrate chain length of O-antigen. Both of theA O-polysaccharide-recombinant fusion protein conjugate vaccines rCTB4573-OPSand rEPA4573-OPSas prepared by usingA with an O-antigen having an extended carbohydrate chain can induce mice to generate specific antibodies againstA, and their antibody titers are significantly improved.

with an O-antigen having an extended carbohydrate chain and use thereof

Growing community of inventors

Beijing, China

Erling Feng